Management of unfit patients with unfavourable non-Hodgkin's lymphomas

Cancer Treatment Reviews

Volumn 35, Issue 6, 2009, Pages 528-532

  Soubeyran, Pierre ^a,b   Mertens, Cécile ^a,c   Bellera, Carine ^a   Mathoulin Pélissier, Simone ^a   Rainfray, Muriel ^b,c  

^a INSTITUT BERGONIÉ   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Chemotherapy; Elderly; Frail; Lymphoma; Unfit

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DOXORUBICIN; MONOCLONAL ANTIBODY; NAVELBINE; PREDNISONE; RITUXIMAB;

CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COMORBIDITY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FRAIL ELDERLY; FUNCTIONAL STATUS; GERIATRIC DISORDER; HEART FAILURE; HUMAN; NEUTROPENIA; NONHODGKIN LYMPHOMA; PATIENT ASSESSMENT; PATIENT CARE PLANNING; PATIENT SAFETY; PATIENT SELECTION; PROGNOSIS; REVIEW; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION;

AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; FRAIL ELDERLY; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; PATIENT SELECTION;

EID: 70349332443     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.04.001     Document Type: Review

References (36)

1. D'Amore F., Brincker H., Christensen B.E., Thorling K., Pedersen M., Nielsen J.L., et al. Non-Hodgkin's lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. The Danish LYEO-Study Group. Ann Oncol 3 (1992) 379-386
2. The Non-Hodgkin's Lymphoma Classification Project. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. Ann Oncol 8 (1997) 973-978
3. Maartense E., Hermans J., Kluinnelemans J.C., Kluin P.M., Vandeijk W.A., Snijder S., et al. Elderly patients with non-Hodgkin's lymphoma: Population-based results in the Netherlands. Ann Oncol 9 (1998) 1219-1227
4. Bastion Y.B., Blay J.Y., Divine M., Brice P., Bordessoule D., Sebban C., et al. Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment, and survival - A groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol 15 (1997) 2945-2953
5. Sonneveld P., Deridder M., Vanderlelie H., Nieuwenhuis K., Schouten H.L., Mulder A., et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 13 (1995) 2530-2539
6. Tirelli U., Errante D., Van Glabbeke M., Teodorovic I., Kluin-Nelemans J.C., Thomas J., et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 16 (1998) 27-34
7. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 235-242
8. Pettengell R., and Linch D. Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma. Br J Haematol 121 (2003) 44-48
9. Sehn L.H., Donaldson J., Chhanabhai M., Fitzgerald C., Gill K., Klasa R., et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23 (2005) 5027-5033
10. Pfreundschuh M., Schubert J., Ziepert M., Schmits R., Mohren M., Lengfelder E., et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9 (2008) 105-116
11. Soubeyran P., Eghbali H., Cany L., Ceccaldi J., Balzon J.C., Rémuzon P., et al. Intermediate and high-grade non-hodgkin's lymphomas in the elderly. Prospective registration study in a regional lymphoma network. Blood 94 Suppl 1 (1999) 524a
12. Monfardini S., Aversa S.M.L., Zoli V., Salvagno L., Bianco A., Bordonaro R., et al. Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. Ann Oncol 16 (2005) 1352-1358
13. Soubeyran P, Khaled H, MacKenzie M, Rozewicz C, de Bock R, Ceccaldi J, et al. Diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma in the frail elderly. Results of the EORTC 20992 trial with a progressive and cautious strategy. Proc Ann Meet Int Soc Geriatric Oncol 2005.
14. Visani G., Ferrara F., Alesiani F., Ronconi S., Catarini M., D'adamo F., et al. R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study. Leuk Lymph 49 (2008) 1081-1086
15. Soubeyran P., Rainfray M., Mathoulin-Pelissier S., Blanc-Bisson C., Mertens C., Blanc J.F., et al. Prediction of early death risk in the elderly with cancer. Results of a prospective multicentric study of 364 patients under chemotherapy. J Clin Oncol 25-18 Suppl 1 (2007) 503s
16. Bellera C., Rainfray M., Mathoulin-Pelissier S., and Soubeyran P. Validation of a screening tool in geriatric oncology: the Oncodage Project. Crit Rev Oncol Hematol 68 Suppl 2 (2008) S22
17. Mohile S.G., Bylow K., Dale W., Dignam J., Martin K., Petrylak D.P., et al. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer 109 (2007) 802-810
18. Balducci L., and Extermann M. Management of cancer in the older person: a practical approach. Oncologist 5 (2000) 224-237
19. Monfardini S., Gridelli C., Pasetto L.M., Soubeyran P., Droz J.P., and Basso U. Vulnerable and frail elderly: an approach to the management of the main tumour types. Eur J Cancer 44 (2008) 488-493
20. Hoerni B., Sotto J.J., Eghbali H., Sotto M.F., Hoerni-Simon G., and Pegourie B. Non-Hodgkin's malignant lymphomas in patients older than 80. 70 cases. Cancer 61 (1988) 2057-2059
21. Thieblemont C., Grossoeuvre A., Houot R., Broussais-Guillaumont F., Salles G., Traulle C., et al. Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 19 (2008) 774-779
22. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
23. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 1937-1947
24. Monti S., Savage K.J., Kutok J.L., Feuerhake F., Kurtin P., Mihm M., et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105 (2005) 1851-1861
25. Lenz G., Wright G., Dave S.S., Xiao W., Powell J., Zhao H., et al. Stromal gene signatures in large-B-Cell lymphomas. The New England Journal of Medicine 359 (2008) 2313-2323
26. Jais J.P., Haioun C., Molina T.J., Rickman D.S., de R.A., Berger F., et al. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 22 (2008)
27. Lam L.T., Wright G., Davis R.E., Lenz G., Farinha P., Dang L., et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 111 (2008) 3701-3713
28. Lenz G., Davis R.E., Ngo V.N., Lam L., George T.C., Wright G.W., et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319 (2008) 1676-1679
29. Lenz G., Wright G.W., Emre N.C., Kohlhammer H., Dave S.S., Davis R.E., et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 105 (2008) 13520-13525
30. Hershman D.L., McBride R.B., Eisenberger A., Tsai W.Y., Grann V.R., and Jacobson J.S. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 26 (2008) 3159-3165
31. MacManus M.P., Seymour J.F., and Hicks R.J. Overview of early response assessment in lymphoma with FDG-PET. Cancer Imag 7 (2007) 10-18
32. Bokemeyer C., Aapro M.S., Courdi A., Foubert J., Link H., Osterborg A., et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43 (2007) 258-270
33. Repetto L., Biganzoli L., Koehne C.H., Luebbe A.S., Soubeyran P., Tjan-Heijnen V.C., et al. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 39 (2003) 2264-2272
34. Morschhauser F., Radford J., Van Hoof A., Vitolo U., Soubeyran P., Tilly H., et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26 (2008) 5156-5164
35. Zinzani P.L., Tani M., Fanti S., Stefoni V., Musuraca G., Castellucci P., et al. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol 19 (2008) 769-773
36. Emmanouilides C., Witzig T.E., Wiseman G.A., Gordon L.I., Wang H., Schilder R., et al. Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm 22 (2007) 684-691